KP 403

Drug Profile

KP 403

Latest Information Update: 16 Nov 2006

Price : $50

At a glance

  • Originator Kaken Pharmaceutical
  • Class Antihypertensives; Benzopyrans
  • Mechanism of Action Potassium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hypertension

Most Recent Events

  • 26 May 2001 Profile reviewed but no significant changes made
  • 20 May 1997 No-Development-Reported for Hypertension in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top